Staar Surgical Co is a manufacturer of lenses... Show more
STAAR Surgical's quarterly results offer a key read on the global shift from laser-based to lens-based vision correction, a trend the company believes is still in its early stages. Its implantable Collamer lenses (ICLs) are positioned at the center of that transition, with China serving as its largest and most important market. Investors watch these earnings closely for evidence that premium lens adoption, particularly EVO+ and toric variants, is driving higher average selling prices and durable demand. This quarter's figures also carry added complexity: the prior-year period included a large deferred China sale that inflated last year's results, making direct comparisons misleading. Understanding the underlying, adjusted growth rate is therefore essential to evaluating the company's real momentum.
STAAR Surgical reported third quarter 2026 net sales of $83.4 million, a 12% decline from $94.7 million in the prior-year period. That headline drop, however, stems from $25.9 million in deferred China sales recognized in the third quarter of 2025 with no corresponding cost of sales. Excluding that item, total revenue rose 21% year over year, with China sales growing 31% to $39.3 million. Outside China, net sales increased 13% to $44.1 million.
Gross margin was 70.9%, down from 82.2% a year ago, reflecting temporary pressures tied to the ERP implementation, freight, tariffs, and inventory provisions. GAAP net income was $5.6 million, or $0.11 per diluted share, compared with $8.9 million, or $0.18 per diluted share, a year earlier. Adjusted EBITDA was $14.4 million, or $0.28 per diluted share. Reported revenue and earnings comfortably exceeded the consensus estimates of roughly $78.7 million in revenue and $0.05 in earnings per share tracked ahead of the release.
Tickeron's AI Screener is an AI-powered stock and ETF (exchange-traded fund) discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to help identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Whether you are tracking earnings movers like STAA or searching for broader opportunities, the AI Screener offers a structured way to narrow the universe and surface actionable candidates.
The market's initial response reflected relief that underlying demand remained robust despite the messy year-over-year comparison. With revenue and earnings both clearing consensus, sentiment centered on the strength of China's lens adoption and the company's ability to convert that demand into higher average selling prices. Still, the gross margin contraction and management's acknowledgment that it could not fully meet lens demand during the quarter tempered enthusiasm. Investors weighed the near-term manufacturing constraints and temporary cost pressures against a debt-free balance sheet, a new buyback authorization, and management's expectation that gross margin will improve in the fourth quarter and into 2027.
Management signaled that gross margin should rise above third-quarter levels in the fourth quarter as lower tariffs and smaller inventory provisions take effect, with further improvement expected in 2027 as unit costs recover. A central theme for investors is supply: with both U.S. and Swiss production facilities running at full capacity, the company is focused on improving product availability and manufacturing yields while expanding capacity to close the gap between shipments and underlying demand.
Product mix will remain a key driver. Higher adoption of EVO+ and toric lenses in China is lifting average selling prices, and the company is pushing deeper into lower-diopter patients, a substantially larger addressable population. On the innovation front, STAAR expects first-in-human trials for two Collamer-based presbyopia products to begin patient enrollment in the coming months, part of a broader ambition to launch a meaningful product every 18 to 24 months.
Investors should also monitor regional dynamics, including currency headwinds in Japan, market softness in South Korea, and the pace of recovery in the Middle East. Tariff exposure is being reduced as China-bound manufacturing shifts to Switzerland, though existing U.S.-made inventory remains subject to tariffs when sold into China. Together, these factors frame a story of solid demand but near-term execution constraints that will shape the quarters ahead.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
a designer of implantable lenses for the eye and delivery systems used to deliver lenses into the eye
Industry PharmaceuticalsOther